Smith & Nephew plc (LON:SN)
1,265.00
+33.50 (2.72%)
At close: Dec 5, 2025
Smith & Nephew Revenue
Smith & Nephew had revenue of $2.96B USD in the half year ending June 28, 2025, with 8.30% growth. This brings the company's revenue in the last twelve months to $5.94B, up 5.35% year-over-year. In the year 2024, Smith & Nephew had annual revenue of $5.81B with 4.70% growth.
Revenue (ttm)
$5.94B
Revenue Growth
+5.35%
P/S Ratio
2.47
Revenue / Employee
$342.61K
Employees
17,349
Market Cap
10.72B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.81B | 261.00M | 4.70% |
| Dec 31, 2023 | 5.55B | 334.00M | 6.40% |
| Dec 31, 2022 | 5.22B | 3.00M | 0.06% |
| Dec 31, 2021 | 5.21B | 652.00M | 14.30% |
| Dec 31, 2020 | 4.56B | -578.00M | -11.25% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Convatec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
Smith & Nephew News
- 24 days ago - Smith & Nephew (SNN) Analyst Rating Update: Target Price Lowered | SNN Stock News - GuruFocus
- 4 weeks ago - Smith & Nephew is Now Oversold (SNN) - Nasdaq
- 4 weeks ago - Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript - Seeking Alpha
- 4 weeks ago - Smith & Nephew plc (SNN) Q3 2025 Sales/ Trading Statement Call - Slideshow - Seeking Alpha
- 4 weeks ago - Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release - Seeking Alpha
- 5 weeks ago - Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - GlobeNewsWire
- 6 weeks ago - UFC® and Smith+Nephew announce multi-year extension of partnership - GlobeNewsWire
- 7 weeks ago - Smith & Nephew (SNN) Downgraded to 'Market Perform' by Bernstein | SNN Stock News - GuruFocus